PEPG · PepGen Inc.

BOSTON --(BUSINESS WIRE)--May 21, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing

– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 – – FREEDOM2 trial open in South Korea, Australia, and New Zealand – – Well-funded with $148.5M of cash as of December 31,

- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates

BOSTON --(BUSINESS WIRE)--Mar. 3, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur,

BOSTON --(BUSINESS WIRE)--Dec. 9, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an

BOSTON --(BUSINESS WIRE)--Dec. 8, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio BOSTON --(BUSINESS WIRE)--Nov. 12, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having received at least one dose – – Recent $115 million financing extends cash runway